Send to

Choose Destination
Cancer Res. 2019 Apr 1;79(7):1624-1634. doi: 10.1158/0008-5472.CAN-18-2867. Epub 2019 Jan 28.

Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity.

Author information

Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, California.
Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway.
Department of Chemistry, Stanford University, Stanford, California.
Department of Chemical and Systems Biology, Stanford University, Stanford, California.
Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, California.
Contributed equally


Localized expression of effector molecules can initiate antitumor responses through engagement of specific receptors on target cells in the tumor microenvironment. These locally induced responses may also have a systemic effect, clearing additional tumors throughout the body. In this study, to evoke systemic antitumor responses, we utilized charge-altering releasable transporters (CART) for local intratumoral delivery of mRNA coding for costimulatory and immune-modulating factors. Intratumoral injection of the CART-mRNA complexes resulted in mRNA expression at the site of administration, transfecting a substantial proportion of tumor-infiltrating dendritic cells, macrophages, and T cells in addition to the tumor cells, resulting in a local antitumor effect. Using a two-tumor model, we further show that mRNA therapy locally administered to one tumor stimulated a systemic antitumor response, curing both tumors. The combination of Ox40l-, Cd80-, and Cd86-encoding mRNA resulted in the local upregulation of proinflammatory cytokines, robust local T-cell activation, and migration of immune cells to local draining lymph node or to an anatomically distant tumor. This approach delayed tumor growth, facilitated tumor regression, and cured tumors in both A20 and CT26 tumor models. These results highlight mRNA-CART therapy as a viable approach to induce systemic antitumor immunity from a single localized injection. SIGNIFICANCE: The mRNA-CART system is a highly effective delivery platform for delivering immunostimulatory genes into the tumor microenvironment for potential therapeutic development.

[Available on 2020-04-01]

Supplemental Content

Full text links

Icon for HighWire Icon for Norwegian BIBSYS system
Loading ...
Support Center